December 2011 in “The Diabetes Educator” This article describes how a new blood glucose management service at the NIH Clinical Center improved safety and patient outcomes for hospitalized patients with diabetes.
5 citations
,
January 2022 in “Proceedings of the Pakistan Academy of Sciences B Life and Environmental Sciences” This review discusses the role of nanoparticles in cancer diagnosis and treatment and outlines their potential to improve outcomes by reducing systemic toxicity and overcoming multidrug resistance, though it reports no new clinical results.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Tailored medication preparation and ongoing education are crucial for effective treatments.
May 2024 in “Open Repository of the University of Porto (University of Porto)” This report details the experiences gained during a pharmacy internship in both hospital and community settings, highlighting the preparation of sildenafil suspensions for hospital use, patient consultations on autoimmune conditions, and educational material creation in community pharmacy, alongside insights into diabetes and ADHD treatments.
March 2017 in “Fundamental & Clinical Pharmacology” This case study reported an improvement in lower limb edema for a patient with type 2 diabetes mellitus after starting dulaglutide treatment, suggesting a potential role of the drug in sodium retention disorders.
This article reviews the contraceptive agent Depo-Provera, discussing its effectiveness, potential side effects, and safety concerns, but reports no new clinical results.
7 citations
,
August 2000 in “Journal of Pediatric and Adolescent Gynecology” This review discusses perceptions and side effects of depot medroxyprogesterone acetate and emphasizes the importance of educating teens to enhance compliance; it reports no new clinical findings.
July 2025 in “Ultrasound in Medicine & Biology” This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.
81 citations
,
February 2000 in “Anti-cancer drugs” In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.
4 citations
,
August 2024 in “PLoS ONE” In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.
8 citations
,
October 1996 in “JAMA” This case report discusses a 17-year-old student's contraceptive use and pregnancy history without providing new research findings.
156 citations
,
August 2014 in “Cochrane library” This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.
September 2021 in “Fertility and sterility” In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.
33 citations
,
January 1979 in “Acta obstetricia et gynecologica Scandinavica” This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.
3 citations
,
December 1997 in “Pediatric Clinics of North America” This article reviews adolescent sexual behavior and emphasizes the importance of hormonal contraception for sexually active teenagers, suggesting that health care providers play a crucial role in addressing their reproductive needs.
November 2024 in “Nanomaterials” This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.
7 citations
,
May 2016 in “European Polymer Journal” This study found that biodegradable hyperbranched polyesters improved the solubility and loading capacity of hydrophobic drugs, with complete pyrene release achieved in 16 days under enzymatic conditions.
64 citations
,
January 1998 in “Drugs” In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.
10 citations
,
May 2016 in “Polymer” This study reports that novel core-ABS nanocarriers efficiently loaded with dexamethasone and finasteride show potential for dermal drug delivery, exhibiting non-toxic interactions with human keratinocyte cells and skin penetration.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.
This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.
46 citations
,
May 2009 in “Maturitas” This study found that taking a daily oral dose of 50mg DHEA for one year had no significant impact on blood lipids, insulin sensitivity, or the endometrium in postmenopausal women with low libido.
14 citations
,
April 2005 in “African Journal of Reproductive Health” This article reviews non-biodegradable progestational subdermal implants as long-acting contraceptives for women, discussing their effectiveness, associated side effects, and implementation challenges without reporting new clinical results.
March 2024 in “BMC women's health” This study found that free testosterone levels were 29% higher with the levonorgestrel implant than with the DMPA injection, which may impact sexual function, mood, and side effects like acne.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.
March 2001 in “Clinical Obstetrics & Gynecology” This paper is a quiz on contraceptive knowledge and reports no new research findings.
This study reported that dupilumab successfully induced remission of chronic, disseminated eczema herpeticum in a six-year-old girl with DOCK8-deficiency hyper-IgE syndrome, achieving complete resolution of herpetic lesions and significant skin, hair, and nail improvement within three months.
January 2025 in “Nanoscale” This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.
April 2026 in “SSRN Electronic Journal”
August 2010 in “Springer eBooks” Hormonal contraceptives are effective for teens but require careful consideration of side effects and individual health.